Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver John Kennedy

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Cancer Immunology, Immunotherapy : CII|June 11, 2022
The impact of body mass index on overall survival in patients with cancer receiving immunotherapy: a dose-response meta-analysisOliver John Kennedy, Marianne Therese Neary
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 10, 2022
Brief Communication on the Impact of β-blockers on Outcomes in Patients Receiving Cancer ImmunotherapyOliver John Kennedy, Marianne Therese Neary
International Journal of Clinical Practice|August 25, 2017
Coffee and kidney diseaseOliver John Kennedy, Paul Roderick, Robin Poole, et al.
Therapeutic Advances in Gastroenterology|May 3, 2016
Coffee, caffeine and non-alcoholic fatty liver disease?Oliver John Kennedy, Paul Roderick, Robin Poole, et al.
Immunotherapy Advances|March 30, 2026
Overall survival by baseline and on-treatment systemic immune-inflammation index in patients with advanced cancer receiving immune checkpoint inhibitors: a large single-centre cohort studyOliver John Kennedy, Rebecca Lee, Fiona Blackhall, et al.
BMJ Open|May 12, 2017
Coffee, including caffeinated and decaffeinated coffee, and the risk of hepatocellular carcinoma: a systematic review and dose-response meta-analysisOliver John Kennedy, Paul Roderick, Ryan Buchanan, et al.
European Journal of Cancer (Oxford, England : 1990)|March 3, 2024
Thyroid dysfunction after immune checkpoint inhibitors in a single-centre UK pan-cancer cohort: A retrospective studyOliver John Kennedy, Nadia Ali, Rebecca Lee, et al.
EJC Skin Cancer|January 19, 2026
Patterns of systemic treatment for melanoma: An insight on trends and costs between 2019-2023 from the English systemic anti-cancer therapy national databaseTommaso Bosetti, Oliver John Kennedy, Rebecca Lee, et al.
The Lancet Regional Health. Europe|January 7, 2026
Cancer diagnoses, referrals, and survival in people with a learning disability in the UK: a population-based, matched cohort studyOliver John Kennedy, Umesh Chauhan, Louise Gorman, et al.
European Urology Oncology|February 20, 2026
Prostate Cancer Care for Men with an Intellectual Disability: A Population-based Cohort Study of Symptoms, Diagnosis, Treatment, and SurvivalOliver John Kennedy, Umesh Chauhan, Louise Gorman, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Cancer Immunology, Immunotherapy : CII|June 11, 2022
The impact of body mass index on overall survival in patients with cancer receiving immunotherapy: a dose-response meta-analysisOliver John Kennedy, Marianne Therese Neary
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 10, 2022
Brief Communication on the Impact of β-blockers on Outcomes in Patients Receiving Cancer ImmunotherapyOliver John Kennedy, Marianne Therese Neary
International Journal of Clinical Practice|August 25, 2017
Coffee and kidney diseaseOliver John Kennedy, Paul Roderick, Robin Poole, et al.
Therapeutic Advances in Gastroenterology|May 3, 2016
Coffee, caffeine and non-alcoholic fatty liver disease?Oliver John Kennedy, Paul Roderick, Robin Poole, et al.
Immunotherapy Advances|March 30, 2026
Overall survival by baseline and on-treatment systemic immune-inflammation index in patients with advanced cancer receiving immune checkpoint inhibitors: a large single-centre cohort studyOliver John Kennedy, Rebecca Lee, Fiona Blackhall, et al.
BMJ Open|May 12, 2017
Coffee, including caffeinated and decaffeinated coffee, and the risk of hepatocellular carcinoma: a systematic review and dose-response meta-analysisOliver John Kennedy, Paul Roderick, Ryan Buchanan, et al.
European Journal of Cancer (Oxford, England : 1990)|March 3, 2024
Thyroid dysfunction after immune checkpoint inhibitors in a single-centre UK pan-cancer cohort: A retrospective studyOliver John Kennedy, Nadia Ali, Rebecca Lee, et al.
EJC Skin Cancer|January 19, 2026
Patterns of systemic treatment for melanoma: An insight on trends and costs between 2019-2023 from the English systemic anti-cancer therapy national databaseTommaso Bosetti, Oliver John Kennedy, Rebecca Lee, et al.
The Lancet Regional Health. Europe|January 7, 2026
Cancer diagnoses, referrals, and survival in people with a learning disability in the UK: a population-based, matched cohort studyOliver John Kennedy, Umesh Chauhan, Louise Gorman, et al.
European Urology Oncology|February 20, 2026
Prostate Cancer Care for Men with an Intellectual Disability: A Population-based Cohort Study of Symptoms, Diagnosis, Treatment, and SurvivalOliver John Kennedy, Umesh Chauhan, Louise Gorman, et al.
Pageof 2